Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05815784 · ClinicalTrials.gov registry record · Phase 2
Myopia Control: a Comparison Study Between Atropine and MiSight
A Phase 2 study of Myopia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 348
- Enrollment target
- 1
- Study location
NCT05815784: Recruiting Phase 2 study of Myopia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
NCT05815784 is a Phase 2 study of Myopia that is actively recruiting participants, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 348 participants, above the 264-participant average among 90 other Myopia trials with a reported enrollment target (32% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05815784, a Phase 2 study of Myopia, is actively recruiting participants, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 348 participants
- Enrollment target
- 1
- Study location
Study Summary
This research project aims to provide additional knowledge of pharmacological and optical methods of myopia control and to gain a better understanding of the biometry of the pediatric eye, which contributes to the onset and progression of myopia. As a result, this study will improving our best practices for myopia control in pediatric patients.
Primary Outcome
change in axial length (as measured by biometry) over a 2-year time period
Conditions Studied
Interventions
- DRUG Atropine
- DEVICE MiSight contact lenses
Study Locations (1)
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2026-03-13 |
| Phase | Phase 2 |
What NCT05815784 shows while recruiting
NCT05815784 is an interventional study that assigns participants to a tested intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap, above the 264-participant average among 90 other Myopia trials with a reported enrollment target (32% higher).
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Atropine is the first listed.
NCT05815784 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05815784 about?
NCT05815784 is a clinical study titled "Myopia Control: a Comparison Study Between Atropine and MiSight". This research project aims to provide additional knowledge of pharmacological and optical methods of myopia control and to gain a better understanding of the biometry of the pediatric eye, which contributes to the onset and progression of myopia. As a result, this study will improving our best pract...
What is the current status of trial NCT05815784?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 348 participants. The study started on 2023-05-02. Estimated completion is 2026-03-13.
What conditions does trial NCT05815784 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT05815784?
The interventions under investigation include: Atropine (DRUG), MiSight contact lenses (DEVICE).
Who is sponsoring clinical trial NCT05815784?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05815784 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05815784's enrollment target sits among peer trials
348 14th of 90 higher than 77 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control
COMPLETED · Phase 2
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Clinical Evaluation of WaveLight Plus LASIK
RECRUITING
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041479 · 348 participants · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05428735 · 348 participants · NA
The DRAGON 2 Trial
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI